CLINICAL PRACTICE GUIDELINES 2nd edition

Schizophrenia and Depression in the peripartum

Dr Helen Chen, Head, Department of Psychological Medicine, KKH Director, Postnatal Depression Intervention Programme

What is the evidence?

- evidence base significantly limited on the risks of psychotropic medication during pregnancy and breastfeeding, esp with newer drugs
- ethical issues with RCTs only from clinical experience, case reports, and birth registry data, TIS (FDA grading C)
- no psychotropic drug has marketing authorisation specifically for pregnant or breastfeeding women.

How to decide management?

 open discussion with patients and their spouses or care-partners, with clear documentation of risks/ benefits considered, and informed consent regarding treatment option.

PERIPARTUM DEPRESSION

Inclusion: major public health issue given its prevalence and impact on mothers, foetuses and infants.

Locally ≈ 12% of pregnant women, 7% of postpartum women suffer from depression reflecting worldwide trends.

PERIPARTUM DEPRESSION

 Antenatal depression a/w substance abuse, poor antenatal compliance or nutrition, and possibly an increased risk of premature labour

 Untreated antenatal depression continues into the postpartum period in up to 50% of the cases

POSTPARTUM DEPRESSION

- Postpartum depression a/w :
 - unfavourable parenting practice
 - impaired mother-infant bonding >>
 impaired intellectual and emotional
 development of the infant
 - gravest outcomes: maternal suicide & infanticide

Screening & Early Recognition

- "During the past month, have you often been bothered by feeling down, depressed or hopeless?"
- "During the past month, have you often been bothered by having little interest or pleasure in doing things?"

"Yes" to either question

"Is this something you feel you need/want help with?"

Specialist perinatal care recommended for women with:

 past or present severe mental illness including schizophrenia, bipolar disorder, psychosis in the postnatal period and severe depression

 previous treatment by a psychiatrist or specialist mental health team including inpatient care

a family history of perinatal mental illness

Treatment of Peripartum Depression

- New onset depression
- Pre-existing depression

New Onset Depression

 Aim: minimise risk of harm to developing fetus or nursing infant, balancing this against the benefits of treatment, and harm of illness

New Onset Depression

- Psychological therapies (formal therapy, nondirective counselling and support) as first-line treatment strategy
- Medication only in severe depression
- Early referral to a specialist with expertise in perinatal mental health recommended, unless depression is mild

Pre-existing depression

- Consider risk of relapse (up to 70%)
 if antidepressants stopped
- Early referral to a psychiatrist with expertise in perinatal mental health is recommended

SCHIZOPHRENIA – in perinatal period

- treatment → impact on fetus or nursing infant vs withdrawal of medications → risk of relapse, illness effects on mother and child
- Gestation timescales and knowledge of fetal development crucial

Mothers with schizophrenia

Lack of interpersonal skills
Mood fluctuations
Cognitive difficulties
Behavioural unpredictability
Side effects of medications – affect flattening
Alcohol and other substances
Lack of social support
Poverty

Seeman MC, Primary Psychiatry 2002; 9(10)

Schizophrenia – preconception and antepartum management

- Treatment individualised, consider:
 - 1) severity of previous episodes,
 - 2) duration of remission since last episode,
 - 3) response to treatment
 - 4) woman's preference after informed discussion

Patient autonomy vs patient needs

Schizophrenia – preconception and antepartum management

 Strategy: minimum effective dose, in divided dosing to minimise peak blood levels (preferrably)

 Recommend urgent consultation with a psychiatrist, preferably one with a special interest in perinatal mental health.

Schizophrenia – preconception and antepartum management

 Avoid abrupt cessation of medications (> increase risk of relapse, and ↓ time to relapse, esp in early weeks of pregnancy when hormonal changes make the woman more vulnerable)

- Folate supplement reduces risk of neural tube defects by 50% → routine use recommended if of childbearing age, esp preconception or pregnant
- Psychotropics can raise prolactin levels → ↓fertility
 Consider alternatives

- Care plans must consider risk management a significant risk of postpartum relapse (1:2)
- Supportive care for the mother with schizophrenia is particularly important to keep her healthy and able to care for her baby.
- Close monitoring is important.

- refrain from giving patients open date reviews with instructions to return for review if symptoms arise
- strongly recommended: patients be monitored regularly through-out pregnancy, esp if medications have been withdrawn, and reinstatement of medications be considered after delivery to minimise risk of relapse

Increase in dose may be needed:
 eg. previous history of postpartum relapse
 (due to puerperium estrogen loss)

 Minimal effective dose in divided dosing if breastfeeding.
 Aim to fit treatment options to support woman's wish to breastfeed rather than recommend stopping

 Refer mothers with schizophrenia to psychiatrists to discuss these options, as safety evidence inconclusive

Due care should be given to screen and manage co-morbid postpartum depression

Schizophrenia – in women of childbearing age

- Special mention in guideline given the needs :
 - 1) Provide psychoeducation on the risk considerations in pregnancy, and
 - 2) Counselling on family planning & sexuality issues
 - Higher risk of unplanned pregnancies
 - Risk with early exposure prior to pregnancy determination
 - Folate supplementation